Aim: To study the protective effects of compound FLZ, a novel synthetic analogue of natural squamosamide, on learning and memory impairment and lesions of the hippocampus caused by icv injection of β-amyloid [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) in mice. Methods: Mice were icv injected with the Aβ 25-35 (15 nmol/mouse), and then treated with oral administration of 75 mg/kg or 150 mg/kg of FLZ once daily for 16 consecutive days. The impairment of learning and memory in mice were tested using step-down test and Morris water maze test. The content of malondialdehyde (MDA) and the expressions of acetylcholinesterase (AChE), Bax, and Bcl-2 in the CA1 region of the mouse hippocampus were measured by biochemical and immunohistochemical analysis, respectively. The pathological damages of hippocampus were observed using a microscope. Results: FLZ (75 mg/kg, 150 mg/kg) significantly attenuated Aβ 25-35 -induced impairment of learning and memory in the step-down test and Morris water maze test. FLZ also reduced pathological damages to the hippocampus induced by Aβ 25-35. Furthermore, FLZ prevented the increase of AChE and Bax, and the decrease of Bcl-2 immunoreactive cells in the CA1 region of the hippocampus, and reduced the increase of MDA content in the hippocampus in mice injected with Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Conclusion: FLZ has protective action against the impairment of learning and memory and pathological damage to the hippocampus induced by icv injection of Aβ 25-35 in mice.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder that is clinically characterized by progressive memory loss and other cognitive impairments. The neuropathological hallmarks of AD include the formation of senile plaque of beta-amyloid (Aβ), neurofibrillary tangles, and synapse and neuron loss in several areas (hippocampus, cortex, amygdale, and others) of the brain [1] . Aβ has been thought to be a critical factor in the pathogenesis of AD. Many studies have found that the accumulation of Aβ in the brain is associated with progressive neuronal death and cognitive deficits [2] [3] [4] . Therefore, preventing the neurotoxicity induced by Aβ might be an optimal strategy for treatment of AD. Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] is considered the shorter toxic fragment exerting neurotoxic effects similar to those produced by Aβ 1-40/42 , such as learning and memory impairment, neuronal apoptosis, cholinergic dysfunction, and oxidative stress [5, 6] , thus Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] is usually used to establish the AD model for study of the neurotoxic properties of Aβ and drug screening.
Because memory loss and cognitive dysfunction are the main clinical symptoms of AD patients, any therapy of AD requires identification of the factors that can confer protection against learning and memory impairment. Compound FLZ ( Figure 1 ) is a novel synthetic cyclic analogue of natural squamosamide from a Chinese herb [7] . Our previous studies have demonstrated that compound FLZ has a strong antioxidant property, and that FLZ protected against the damage and apoptosis of primary cultured rat brain neurons and PC12 cells exposed to hydrogen peroxide, glutamate,
N-methyl-D-aspartate (NMDA), dopamine, MPP +
, and ischemia-reoxygenation. FLZ also improved abnormal behavior due to the functional disturbance of dopaminergic and cholinergic neurons in mice, indicating that FLZ possesses a neuroprotective property [8] . It is very interesting to study whether FLZ can attenuate learning and memory impairment, and pathological and biochemical damages in the hippocampus induced by icv injection of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in mice.
Materials and methods
Reagents Compound FLZ was kindly provided by Professor Xiao-tian LIANG in the Department of Pharmaceutical Chemistry, Institute of Materia Medica, Chinese Academy of Medical Sciences. FLZ, a white powder with 99% purity, was suspended in 0.5% (w/v) sodium carboxymethyl cellulose (CMC-Na) for oral administration. Tacrine (Sigma Chemical, St Louis, MO, USA) was dissolved in saline. Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (Sigma) was dissolved in sterile double-distilled water at a concentration of 2 g/L, and incubated at 37 °C for 4 d for aggregation, and then stored at -20 °C for use [9] . Anti-acetylcholinesterase (AChE) polyclonal antibody was purchased from Boster Biotechnology (Boster, Wuhan, China). Bcl-2 and Bax polyclonal antibodies, second antibody and diaminobenzidine tetrahydrochloride (DAB) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Other reagents were of analytical grade from Beijing Chemical Company (Beijing, China).
Animals Male ICR mice weighing 23-27 g were obtained from the Center of Experimental Animals, Chinese Academy of Medical Sciences (Grade II, Certificate No SCXKJing2004-0001). The mice were housed 5 or 6 per cage in a thermoregulated environment (23±1 °C, 50%±5% humidity) with free access to food and water, under a 12 h light/dark cycle. All animal experiments followed the instructions of the Committee for Care and Welfare of Laboratory Animals in Chinese Academy of Medical Sciences and Peking Union Medical College.
Aβ 25-35 injection and drug treatment The icv injection of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] was performed as described in a previous study [6] . Mice were lightly anesthetized with ether. The aged Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] or saline at a volume of 7.5 µL was gradually injected into the right ventricle by a 28-gauge stainless-steel needle, with the following stereotaxic coordinates (in mm) from the bregma: A: -0.22, L: 1.0, V: 2.5. The injection point had already been confirmed at ventricle by injection of Indian ink in stead of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide in preliminary experiments. The day after icv injection, mice were randomly divided into groups including: control, Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] model, FLZ (75 mg/kg, 150 mg/kg), and tacrine (15 mg/kg). The FLZ, tacrine and vehicle (0.5% CMC-Na) were administered by gavage to mice once a day for 16 d. To observe the memory and learning function of mice, the stepdown test was started on d 8 and the Morris water maze test on d 11 after the injection of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The learning and memory tests were carried out between 9:00 AM and 18:00 PM.
Step-down test Amnesia in mice was examined through the step-down test on d 8 after the Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide injection. The apparatus (Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China) was a transparent acrylic cage . An insulated platform was fixed in the center of the grid floor. During the training, each mouse was kept in the cage for 3 min to adapt to the environment before electricity was delivered to the grid floor for 5 min. The retention test was carried out 24 h after the above training test. The grid floor was delivered with 36 v electricity, individual mice were placed on the insulated platform and the step-down latency and the number of errors within 5 min was recorded.
Morris water maze test The apparatus of Morris water maze (Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China) test is a white circular pool, 120 cm diameter and 40 cm deep, randomly divided into 4 quadrants. Milk powder was put into the pool to render the water opaque. The water temperature was maintained at 23±1 °C. A transparent Plexiglas platform was placed 2 cm below the water surface in the middle of one quadrant. The position of the platform was unchanged during the training trials. Two training trials per day were conducted for 5 consecutive days from d 11 after the injection of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . In each trial, a mouse was placed in the water faced to the pool wall at one starting position. The latency to find the platform was recorded up to 2 min. Mice that found the platform were allowed to remain on the platform for 30 s, and were then returned to the home cage. If the mouse could not find the platform within 2 min, it was gently guided to find the platform by the experimenter, and allowed to remain on the platform for 30 s, and the latency was recorded for 2 min. Data of each mouse behavior were collected by a video camera linked to a computer through an image analyzer. The total sum of latency in two trials of each mouse was counted as the individual result of a mouse per day. The mean latency was calculated by all tested mice per group per day.
At the end of the training period, mice were tested on a spatial probe trial in which the platform was removed, and they were allowed to swim freely for 2 min. The latency of the location of first crossing the platform and the number of crossings of the platform were recorded.
Malondialdehyde (MDA) measurement After completion of the Morris water maze behavior observation, 9-10 mice in every group were killed by decapitation. The hippocampus of the brain was rapidly removed and placed on ice. The dissected tissue was weighed and homogenized with cold 0.9% physiological saline. MDA content was determined by the thiobarbituric acid method. 1,1,3,3-tetramethoxypropane was used as a standard [10] .
Pathology examination of brain tissues
After completion of the above behavior tests, 4 mice in every group were anesthetized with pentobarbital sodium (50 mg/kg, ip), and the brains were transcardially perfused with phosphate buffer solution (PBS, pH 7.4), followed by 4% paraformaldehyde in PBS (pH 7.4). The brains were removed and kept overnight in PBS containing 4% paraformaldehyde at 4 °C, and embedded in paraffin. Sections of 5-µm thickness were stained with hematoxylin and eosin. The lesions of brain tissues were observed with light microscope (NIKON E600, Japan) and the images were collected by image analysis system (Image Pro-Plus 7200, America, SONY 3CCD, Japan).
Immunohistochemistry assay of AChE, Bcl-2, and Bax After the brains were fixed as above, they were removed and kept overnight in PBS containing 20%-30% sucrose and 4% paraformaldehyde at 4 °C. Coronal sections of 35-µm thickness were cut using a cryostat at the hippocampus. Immunohistochemistry was performed as described in a previous study [11] [12] [13] . The primary antibodies were AChE (1:500), Bcl-2, and Bax (1:200). Immunostaining was visualized by the peroxidase method with a biotinylated anti-rabbit secondary antibody and diaminobenzidine oxidation (ABC kit, Santa Cruz). The primary antibody was replaced with normal serum in negative control.
Four mice were taken from each group for quantitative immunohistochemistry. One in every four sections was taken from a continuous series of sections prepared from hippocampal tissue. Six sections were selected in each mouse, so 24 sections of each group were read under a ×10 objective, and the number of positively stained cells in each group was counted. The mean of the number of positively stained cells was calculated from 24 sections of each group [11] . Statistical analysis Data are expressed as mean±SEM. Statistical analysis was performed by one-way ANOVA followed by least significant difference test. In all tests, P<0.05 was considered as statistically significant.
Results

Effect of FLZ on the learning and memory impairment induced by icv injection of Aβ 25-35 in mice
In the step-down test, the icv injection of aged Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (15 nmol/mouse) induced a significant decrease of the avoidance latency and increase of the number of errors, and also the step-down percentage of mice from the platform increased significantly (P<0.05). Oral administration of FLZ (75 mg/kg, 150 mg/kg) and tacrine (15 mg/kg) significantly improved the above impairments of learning and memory induced by Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in mice (P<0.05, Table 1 ). The latency of FLZ treated groups was restored to near that of the normal control group. The number of errors and step-down percentage were also improved markedly.
Furthermore, the Morris water maze was used to test the spatial learning and memory of each mouse from d 11 till d 16 Figure 2 ).
The spatial probe trial was performed to examine whether the mice had remembered the position of the platform. In comparison with the control group, the latency of location for first crossing the platform for mice in the Aβ 25-35 model group increased (P<0.05), while the number of crossings of the platform for mice decreased (P<0.05). The treatment of mice with FLZ (75 mg/kg, 150 mg/kg) and tacrine (15 mg/kg) significantly shortened the latency of first-crossing the platform and increased the number of crossings of the platform within 2 min (P<0.05, Table 2 ).
All the results of the above two behavioral tests indicated that FLZ protected against the impairment of learning and memory function of mice induced by Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] .
Effect of compound FLZ on the MDA level in the hippocampus of mice icv injected with Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] After completing the behavior test of Morris water maze test, the MDA level in the cerebral hippocampus of 9-10 mice per group was determined. The icv injection of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] induced a significant increase in MDA level in the hippocampus (P<0.05). The treatment with FLZ (75 mg/kg, 150 mg/kg) and tacrine (15 mg/kg) markedly decreased MDA levels in the hippocampus of Aβ 25-35 -treated mice ( Table 3) .
Effect of FLZ on the pathological injury of the hippocampus induced by icv injection of Aβ 25-35 in mice
No remarkable neuronal abnormalities in the hippocampus from mice of the normal control group were observed, while all examined brains of Aβ 25-35 model group mice showed degeneration of neurons in the hippocampus and disorder of the array of neurons. The body of neuron became short and deeply stained with dye. Some neurons were shrunk and necrosed. Whereas the neurons in the FLZ (75 mg/kg, 150 mg/kg) and tacrine (15 mg/kg) group mice were close to that of normal control group, indicating that FLZ protected against the injuries of the hippocampus induced by Aβ 25-35 injection (Figure 3) .
Effect of FLZ on AChE, Bcl-2, and Bax immunoreactivity in the hippocampus cells of mice icv injected with Aβ 25-35
There were few AChE and Bax immunoreactive neuronal cells The results of Bcl-2 immunochemical staining showed that the hippocampal CA1 region of control group mice contained abundant and darkly stained Bcl-2 immunoreactive cells (Figure 4, 5) . The marked cells had long processes. In the hippocampal CA1 region of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -treated mice, the number of Bcl-2 immunoreactive cells was less than that of control group mice (P<0.05), the staining was light, and the marked cells had few processes. There were more Bcl-2 immunoreactive cells in the hippocampal CA1 region of FLZ (150 mg/kg) and tacrine-treated mice in contrast to Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -treated mice (P<0.01), and the immunoreactive cells had long processes. The staining was near to that of control group mice.
Discussion
Animal models are playing a critical role in ongoing attempts to understand the pathology and screen therapeutics of AD. Although no available model can meet all the full pathologic spectrum of AD disease, the injection of Aβ into the brain was shown to impair learning and memory, and elicit a degree of Alzheimer's-type neurodegeneration [2] [3] [4] [5] [6] . The important point of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -induced amnesia is the influence of the physical state of the peptide, aggregated or soluble, at the time of administration. The in vitro incubation of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] leads to the formation of stable oligomeric aggregates, which contain an increased proportion of β-sheet structure that appears to be an important feature of the β-amyloid-induced neurotoxicity. This aggregation mimics in vitro the slow aging process that in vivo leads to the formation of the senile plaques [14, 15] . In the present study, a single icv injection of aged Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] to mice induced a significant impairment of learning and memory in step-down test and Morris water maze test, and obvious pathological lesions of the hippocampus. In mammals, the hippocampus is a critical neural structure in the early stage of memory formation. The impairment of memory formation is caused by damage in the hippocampus and associated areas of the temporal cortex. The deposition of Aβ first forms in temporal cortical regions including the hippocampus [16] . Some researchers reported that Aβ-induced injury of the hippocampus was associated with impairment in learning and memory beside biochemical changes and neuronal degeneration [12, 17, 18] . Compound FLZ was shown to prevent the neurotoxicity of Aβ 25-35, as it significantly attenuated the learning and memory impairment and pathological injury of hippocampus in mice injected with Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] .
Apoptosis is considered as the main cause of the loss of cholinergic neurons in AD. Several authors reported that Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] induced the neuronal degeneration through an apoptosis pathway in vitro and in vivo [19, 20] . Bcl-2 family proteins play a pivotal role in regulating apoptotic cell death, some of which members, such as Bcl-2 and Bcl-x L , inhibit apoptosis and others such as Bax induces cell apoptosis. The relative ratio of proapoptotic and antiapoptotic proteins is important to determine cell survival or death [21] . The authors found that Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] increased the expression of proapoptotic protein Bax and decreased the expression of anti-apoptotic protein Bcl-2 in the CA1 region of hippocampus, indicating that Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -induced pathological injury of the hippocampus was related to cell apoptosis. Compound FLZ exerted a significant anti-apoptotic effect through modulating the expression of Bcl-2 and Bax protein in the CA1 region of the hippocampus, which resulted in protection against pathological injury of the hippocampus and impairment of learning and memory.
Several studies with AD models demonstrated that Aβ increases AChE expression and AChE activity not only in cell culture but also in the intact brain [22, 23] . AChE may promote beta-amyloid plaque formation and also increase the Aβ toxicity as reported by Rees et al [24] . Also, there is evidence to indicate that AChE is an exacerbating factor in the apoptosis of neurons, and plays a key role in the procession of apoptotic cell death. The apoptotic neurons can then secrete higher levels of AChE into the brain. This cascade amplification leads to progressive neuronal loss, which is the hallmark of AD [25, 26] . In addition, cholinergic system dysfunction of AD is correlated with cognitive impairment. It was reported that acetylcholine (ACh) levels in the cerebral cortex and hippocampus were significantly decreased by centrally administered Aβ in animals [9, 27] . AChE is a key enzyme in the catabolic metabolism of ACh. Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -enhanced AChE expression and AChE activity might decrease the ACh level. In the present study, the icv injection of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] resulted in a significant increase of AChE expression, and compound FLZ markedly attenuated the increase of the number of AChE immunopositive cells in the CA1 region of the mouse hippocampus induced by icv injection of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . So, we considered that the inhibition of FLZ on AChE expression may be involved in anti-apoptosis and improvement of amnesia in mice injected with Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . We also speculated that the inhibitory effect of FLZ on AChE expression might lead to an increase in acetylcholine level through inhibition of acetylcholine hydrolysis, which thereby enhanced the cholinergic function and improved the impairment of learning and memory. To confirm this speculation, direct measurement of hippocampal acetylcholine level and AChE activity is needed in future experiments.
Multiple lines of evidence indicated that oxygen free radicals (ROS) were involved in Aβ-induced neuronal apoptosis and death. Aβ can induce intracellular ROS production, which causes peroxidation of protein and lipid in neurons [28] . Aβ itself can transform into a radical state and further interacts with neuronal membranes [29] . MDA is an end product of lipid peroxidation of biomembranes, and the MDA content usually reflects the level of lipid peroxidation and indirectly reflects the extent of injury. The icv injection of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] induced a significant increase of MDA content in the mouse brain hippocampus, indicating that Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] induced lipid peroxidation of neurons. FLZ was shown to have obvious antioxidant property, and also protected against oxidative damage and apoptosis of neurons induced by many toxins [8] .
In the present study, we confirmed that FLZ significantly decreased the MDA content in the hippocampus of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] treated mice, suggesting that FLZ has a protective action against oxidative damage of neurons induced by Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Some antioxidants such as vitamin E were reported to eliminate Aβ-induced apoptosis and slow the progression of AD [30, 31] . Xiao et al reported that the protective action of huperzine A and B and tacrine (AChE inhibitor) against Aβ toxicity to PC-12 cells was not cholinesterase-dependent but might be through an antioxidant pathway [32] . So, it appears that therapeutic efforts aiming at the removal of free radicals formation or preventing their damage to related neurons may be beneficial in pharmacol-therapy of AD.
The reason why tacrine, an AChE inhibitor, was selected as a positive control in the present study should be made clear. This was because tacrine was the first drug approved to treat AD by the FDA in the USA [33] , and tacrine was known to attenuate the impairment of leaning and memory induced by icv injection of Aβ 25-35 [9] . Tacrine also showed neuroprotective action against Aβ 25-35 -induced oxidative injury and H 2 O 2 -induced apoptosis [32, 34] . The present results showed that both tacrine and FLZ have similar neuroprotective effect on icv injection of the Aβ 25-35 model in mice. However, tacrine has been known to cause liver toxicity in AD patients by approximately 50% and has peripheral side effects [35] . Compound FLZ of the studied dosages had no such effects in mice. The acute oral LD 50 of FLZ was over 5 g/kg body, indicating FLZ is a low toxicity compound. Moreover, not like tacrine, FLZ is not an inhibitor of AChE activity [8] . In summary, FLZ significantly attenuated learning and memory deficits as well as pathological and biochemical injuries of hippocampus in mice induced by icv injection of aged Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] through the neuroprotective pathway.
